Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-L Raoul

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer CentersY Bécouarn, M Ychou, M Ducreux, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 25, 2013
Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising conceptE Garin, L Lenoir, J Edeline, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2009
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)M Ychou, J-L Raoul, J-Y Douillard, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 27, 2023
Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR)Julie Veziant, Olivier Bouché, T Aparicio, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2018
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trialJ B Bachet, O Lucidarme, C B Levache, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 10, 2012
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancerA Gonçalves, M Gilabert, E François, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatmentA R Thierry, S El Messaoudi, C Mollevi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 13, 2016
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized studyS Faivre, P Niccoli, D Castellano, et al.
Oncologie (Paris, France)|July 21, 2015
Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (<i>Observatoire dédié au Cancer Bretagne / Pays de la Loire</i>)J P Metges, M A Lebot, R Faroux, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer CentersY Bécouarn, M Ychou, M Ducreux, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 25, 2013
Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising conceptE Garin, L Lenoir, J Edeline, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2009
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)M Ychou, J-L Raoul, J-Y Douillard, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 27, 2023
Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR)Julie Veziant, Olivier Bouché, T Aparicio, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2018
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trialJ B Bachet, O Lucidarme, C B Levache, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 10, 2012
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancerA Gonçalves, M Gilabert, E François, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatmentA R Thierry, S El Messaoudi, C Mollevi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 13, 2016
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized studyS Faivre, P Niccoli, D Castellano, et al.
Oncologie (Paris, France)|July 21, 2015
Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (<i>Observatoire dédié au Cancer Bretagne / Pays de la Loire</i>)J P Metges, M A Lebot, R Faroux, et al.
Pageof 9